Glutathione studies use different amounts, routes and schedules for different research questions. The clearest IV example in the studies below is 1,400 mg three times weekly for four weeks in a small Parkinson's disease trial. That trial did not find a statistically significant improvement in its principal symptom scores. Oral and lozenge studies describe other formulations and outcomes; their amounts do not establish a subcutaneous injection protocol.
Glutathione dosage in published human studies
| Study | Amount and route | Duration and participants | Outcome studied |
|---|---|---|---|
| Hauser et al., 2009 | 1,400 mg IV, three times weekly | Four weeks; 21 people with Parkinson's disease randomized to glutathione or placebo | No statistically significant between-group difference in changes in UPDRS symptom scores |
| Richie et al., 2015 | 250 or 1,000 mg orally each day | Six months; 54 nonsmoking adults in a randomized, placebo-controlled trial | Glutathione stores measured in blood and other body compartments |
| Handog et al., 2016 | A glutathione-containing lozenge daily; the indexed abstract does not specify its milligram amount | Eight weeks; 30 Filipino women in an open-label, single-arm study | Melanin indices compared with participants' own baseline |
| Weschawalit et al., 2017 | 250 mg daily of reduced glutathione (GSH), oxidized glutathione (GSSG), or placebo, taken orally | 12 weeks; randomized, double-blind, three-arm study | Skin measurements including melanin index and wrinkles |
What the IV trial actually establishes
Hauser and colleagues assigned 11 participants to glutathione and 10 to placebo. The research schedule totals 4,200 mg per week: 1,400 mg multiplied by three administrations. The symptom-score differences did not reach statistical significance. This is a specific research regimen in Parkinson's disease, rather than evidence of a universal weekly amount for skin, general wellness or another injection route.
Correcting the skin-study comparison
The Handog study was a daily lozenge study with 30 participants and no separate placebo group. It was not a 60-person IV randomized trial using 500 mg twice weekly. Its change from baseline cannot establish that an IV or subcutaneous schedule produces the same result.
From the FormBlends catalog
Glutathione Injectable
Injectable antioxidant support for cellular wellness · From $119/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Glutathione Injectable →The Weschawalit trial provides a separate oral comparison: 250 mg daily of GSH or GSSG versus placebo for 12 weeks. The authors reported changes in skin measurements, with findings varying by measured site. It does not provide a head-to-head comparison against an injected formulation.
What 600 mg, 1,000 mg and 1,500 mg labels mean
Those numbers may describe total container contents or an amount per administration. The label needs to identify which. The trials above do not create a validated injection ladder in which 600 mg is a starting amount, 1,000 mg is the standard and 1,500 mg is an escalation.
The 1,000 mg daily amount in the Richie trial was oral supplementation. The study measured glutathione stores over six months, rather than establishing a 1,000 mg IV wellness session or proving an equivalent injected amount.
Milligrams, concentration and weekly totals
Total contents describes all the glutathione in a container. Concentration describes milligrams per milliliter of solution. Amount per administration and frequency determine a weekly total. A concentration calculation alone does not choose an amount or schedule.
For comparison, 250 mg daily totals 1,750 mg over seven days. The IV research schedule above totals 4,200 mg weekly. Comparing these totals does not establish equivalent exposure or effects because the route, formulation, population and measured outcome differ.
Frequently asked questions
Is there one evidence-based weekly injection amount?
The cited studies do not establish a shared weekly protocol across skin outcomes, Parkinson's disease and general wellness. The research question and route need to match the claim.
Does a skin-lightening lozenge study prove an injection schedule?
No. The Handog study tested a lozenge, not an injection. Its study design also lacked a separate placebo group.
Did the oral study find no absorption?
The Richie trial measured increased glutathione stores after daily oral supplementation. A blanket claim that oral glutathione cannot affect body stores does not describe those results.
Which factors matter when comparing two protocols?
Compare the formulation, route, amount, frequency, duration, participant population, control group and measured outcome together. A shared ingredient name or weekly milligram total is only part of that comparison.
Related glutathione guides
Study sources
- Hauser et al.: IV glutathione pilot trial in Parkinson's disease
- Richie et al.: oral supplementation and glutathione stores
- Handog et al.: open-label glutathione lozenge study
- Weschawalit et al.: oral GSH and GSSG skin measurements
Ready when you are
Glutathione Injectable
Injectable antioxidant support for cellular wellness · From $119/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Glutathione Injectable →